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Complementary and alternative medicine (CAM) including Japanese Kampo is known
to have anticancer potential. An increasing number of cancer survivors are using
CAM for disease prevention, immune system enhancement, and symptom control.
Although there have been abundant previous clinical reports regarding CAM, scientific
investigations aimed at acquiring quantifiable results in clinical trials, as well as basic
research regarding CAM, have only recently been undertaken. Recent studies suggest
that CAM enhancement of immune function is related to cytokines. This review provides
a translational aspect of CAM, particularly Hozai in Kampo from both scientific and
clinical points of view for further development of CAM for cancer treatment.
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Introduction
Common side eﬀects of cancer and cancer treatments that patients try to manage are related
to the domains of mental and physical health-related quality of life (HRQoL). Although many
patients with cancer are suﬀering, they may not be fully aware of less conventional and potentially
alleviating resources (Carlson et al., 2004). To provide a better understanding of these broad
resources, the National Center for Complementary and Alternative Medicine has categorized
complementary and alternative medicine (CAM) to include health care systems, practices and
products/medicines related to mind and body well-being (Monti et al., 2008).
Cancer patients have used CAM for the purposes of wellness, immune function, disease
prevention and pain management. Notably 20–30% of cancer survivors reported using CAM for
cancer prevention, treatment, symptom management, psychological distress, and other conditions
(Sohl et al., 2014). Recent surveys have indicated that among cancer survivors and those without
cancer, respectively 2/3 and 1/2 used CAM in their lifetime. However, when asked if they used CAM
within the last year, about 2/5 from both groups reported use, but the highest use of CAM (∼3/4)
has been reported from cancer patients during cancer therapy (Eng, 2010). These surveys revealed
that cancer survivors are more likely to use CAM when compared with healthy people (Mao et al.,
2011; Sohl et al., 2014). In another study, it was found that 1,666 long-term cancer survivors were:
predominately female (62%), older (mean age = 69.5 years) and had breast, prostate, colorectal,
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ovarian, and endometrial cancers. Thus, when a cancer patient is
treated, CAM is selected as one of the core treatments to support
a patient’s HRQoL.
Deng et al. (2009), “the evidence-based clinical practice
guidelines for health care providers” were issued by the Society
for Integrative Oncology to help decide when to incorporate
complementary health approaches into the care of cancer
patients. Some studies note that when some conventional
therapies and CAM approaches are used jointly, the control
of cancer symptoms and treatment side eﬀects might improve
patient HRQoL (Deng and Cassileth, 2005; Deng et al., 2009).
Other studies suggest that some complementary approaches,
such as herbs, Kampo, acupuncture, natural food including
ginger, massage therapy, yoga, and mindfulness-based stress
reduction may help to control symptoms experienced by cancer
patients and caused by cancer chemotherapy (Mehling et al.,
2007; Ledesma and Kumano, 2009; Elkins et al., 2010; Cramer
et al., 2012).
In Japan, CAM has been used predominantly in a clinical
setting (Yamashita et al., 2002; Hottenbacher et al., 2013).
The most commonly used therapeutic modalities in Japan
are massage, vitamins, natural foods, dietary supplements,
acupressure, and Kampo (Hori et al., 2008).
Although the majority of CAM users felt that CAM treatment
was eﬀective, almost two-thirds of cancer patients did not seek
information or guidance from their physician (Hyodo et al.,
2005). Additionally, clinical oncologists do not agree on the
beneﬁts of CAM as related to cancer treatment, because they
consider CAM treatment options to lack suﬃcient evidence.
Besides, they are concerned about the likelihood of drug
interactions with an anticancer drug. Thus oncologists do not
recommend CAM treatments to patients, and they do not
recommend quitting CAM if the patient was already using it
(Hyodo et al., 2003).
The number of clinical studies investigating the therapeutic
beneﬁts of CAM is increasing, therefore we will focus on clinical
studies and basic research regarding CAM that might further the
development of potential new therapies for cancer patients.
The Clinical Use of Kampo for Cancer
Patients in Japan
The theories and the methods of diagnosis in Japanese
herbal medicine (Kampo) are distinctly diﬀerent from Western
medicine (Yu et al., 2006). Though Kampo originated from
traditional Chinese medicine, it was adapted to Japanese culture
(Yu et al., 2006). Kampo doctors in Japan have prescribed
hundreds of Kampo formulas and the Ministry of Health, Labor
and Welfare have approved nearly 150 formulas to date. There
are numerous Kampo components used by Kampo doctors in
Japan, and 2–15 of uniform parts are in every Kampo formula
(Eﬀerth et al., 2007). The majority of formulas are produced
via a strict manufacturing process (Ohtake et al., 2004), and
understanding the pharmacological mechanisms to analyze the
active compounds in Kampo formulas with scientiﬁc methods is
vital.
Since each Kampo formula consists of many types of
compounds with diﬀerent physicochemical properties, it’s hard to
obtain an overall view of Kampo. However, progress in methods
of scientiﬁc analysis has now made it possible to identify each
Kampo formula by using the “ﬁngerprint pattern” provided
by three-dimensional high performance liquid chromatography
(3D-HPLC) analysis (Ohtake et al., 2004). Kampo formulas
are eﬀective to alleviate the symptoms of cachexia, such as
fatigue and anorexia, and they also reduce pain and improve
the gastrointestinal side eﬀects of anti-cancer drugs, including:
diarrhea, nausea, and vomiting (Qi et al., 2010).
A majority of physicians (∼64%) surveyed reported
prescribing Kampo medicines to help control cancer-related
symptoms such as numbness/hypoesthesia, constipation,
anorexia/weight loss, muscle cramps, and languor/fatigue.
Kampo treatment was also found to extend signiﬁcantly the
survival of patients with uterine cervical cancer (Takegawa et al.,
2008; Gao et al., 2012). The primary concern of physicians thus
far has been in regards to dosage regulation (Iwase et al., 2012).
Western medicine uses a diagnosis approach based on the
disease and symptomology while Kampo emphasizes patient-
based diagnosis (Yu et al., 2006). In this way, “Kampo uses a
treatment ‘formulation corresponding to Sho”’ where “Sho is the
patient’s symptoms at a given moment” (Yu et al., 2006). When
treating a patient, Japanese practitioners use a Sho diagnosis to
tailor the Kampo formula (Yu et al., 2006). Hozai is selected
according to ‘Sho,’ i.e., the patient’s condition from the Kampo
point of view. Four diagnostic procedures of observation are
necessary to determine the optimum formula: listening/smelling,
questioning, and evaluation of pulse and abdominal patterns.
When the patient has psychological symptoms such as insomnia,
depression or irritation, together with autonomic nervous system
symptoms such as gastrointestinal troubles and moist skin,
Hochu-ekki-to is selected. If the patient does not have such
symptoms and the skin is dry, Juzen-taiho-to or, especially when
the patient complains of respiratory symptoms such as cough and
shortness of breath, Ninjin-yoei-to is selected.
Hoshino et al. (2012) described ‘Hozai’ and ‘Sho’ as follows.
Hozais are a group of formulas that invigorate patients who
have lost mental and physical energy due to various causes
including cancer. Kampo formulas containing Ginseng radix
and Astragali radix are called ‘Jingizai’ (Ginseng and Astragali
containing drug group) and are typical Kampo Hozais. Hochu-
ekki-to, Juzen-taiho-to, and Ninjin-yoei-to are the three major
Hozais and are the ones most frequently used for cancer patients.
Cancer survivors suﬀer from several side eﬀects of anti-cancer
therapy, including eﬀects of chemotherapy, radiation therapy,
and hormone therapy. Numerous reports have shown the impact
of Hozai in improving the HRQoL of cancer patients (Horie et al.,
1994).
Kampo and Cytokine in Cancer
The number of articles concerning the eﬀects of Kampo
formulas on cancer patients is on the increase (Satoh et al.,
2002; Molassiotis et al., 2009; Okumi and Koyama, 2014;
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Table 1). Many of these studies have focused on the eﬀects
of medicinal herbal combinations on cytokine activity. These
studies demonstrated that herbal mixture extracts have eﬀects on
at least one cytokine. The most commonly studied cytokines were
interleukin (IL)-4, IL-6, IL-10, tumor necrosis factor (TNF)-alpha
and interferon (IFN)-gamma (Burns et al., 2010). The therapeutic
success of many formulas may be somewhat due to impacts on
cytokines, which have revealed changes in their gene and protein
expressions (Burns et al., 2010).
Numerous cytokines have been linked to symptoms of cancer
patients. The equilibrium between proinﬂammatory and anti-
inﬂammatory cytokines may play a signiﬁcant function in the
TABLE 1 | Efficacy of herbal medicine.
Formula Model Reported outcome Study Reference
Hochu-ekki-to Hepatoma G0/G1 arrest In vitro Kao et al. (2001)
Hochu-ekki-to Peripheral blood mononuclear
cells (PBMC)
Stimulation of PBMC to produce G-CSF and TNF-alpha In vitro Kao et al. (2000)
Hochu-ekki-to Listeria monocytogenes Enhancement of IFN-γ production from infant CD4+ T cells In vivo Yamaoka et al. (2001)
Hochu-ekki-to Ear swelling Suppression of the increase in IL-4 by
2,4,6-trinitro-1-chlorobenzene
In vivo Nakada et al. (2002)
Hochu-ekki-to Cancer Enhancement of NK activity In vivo Cho et al. (1991)
Hochu-ekki-to Asthma Reduction in Th2 responses (IL-4↓, -5↑) In vivo Ishimitsu et al. (2001)
Hochu-ekki-to Endometrial carcinoma Decrease in the expression of c-jun, TNF-alpha and
estrogen receptors (ERs)-alpha and -beta
In vivo Onogi et al. (2006)
Hochu-ekki-to Ovalbumin – entrapped
biodegradable microparticles
Enhancement of the mucosal IgA antibody response In vivo Matsumoto et al.
(2010b)
Hochu-ekki-to Breast cancer Stimulated phosphorylation of c-Jun NH2-terminal kinase In vivo Volate et al. (2009)
Hochu-ekki-to Colon cancer Amelioration of cachexia In vivo Yae et al. (2012)
Hochu-ekki-to Influenza Increase in the production of GM-CSF In vivo Dan et al. (2013)
Hochu-ekki-to Genitourinary cancer Effective for anorexia Clinical Kuroda et al. (1985)
Hochu-ekki-to Mycosis fungoides Partial improvement in skin eruption Clinical Tokura et al. (1998)
Hochu-ekki-to Cancer Improvement in cancer-related fatigue Clinical Jeong et al. (2010)
Juzen-taiho-to Human peripheral blood
mononuclear cells
Increase in the production of GM-CSF In vitro Kubota et al. (1992)
Juzen-taiho-to Hepatoma Inhibition of hepatocarcinogenesis In vitro
and in
vivo
Tatsuta et al. (1994),
Ohnishi et al. (1998)
Juzen-taiho-to Mononuclear cells and normal
mice
Increase in the expression of IL-12 in the early stage, and
IL-18
In vitro
and in
vivo
Fujiki et al. (2008)
Juzen-taiho-to B16 melanoma Increase in the production of IL-12 In vivo Matsuda et al. (2011)
Juzen-taiho-to Estradiol-related endometrial
carcinoma
Suppression of estrogen-induced c-fos/jun-expression In vivo Niwa et al. (2001)
Juzen-taiho-to Hepatoma Inhibition of Kupffer cell-induced oxidative stress Clinical Tsuchiya et al. (2008)
Ninjin-yoei-to Human peripheral blood
mononuclear cells
Increase in the production of GM-CSF In vitro Okamura et al. (1991)
Ninjin-yoei-to Healthy individuals Enhancement of natural killer cell activity Clinical Kamei et al. (1998)
Ninjin-yoei-to Lung carcinoma Improvement in cough and anorexia
Decrease in tumor marker (CEA and CA19-9) levels
Clinical Kamei et al. (2000)
Ninjin-yoei-to Pulmonary Mycobacterium
fortuitum infection
Improvement in subjective symptoms
Conversion to smear negative
Clinical Nogami et al. (2006)
Rikkunshito Cisplatin-induced anorexia Improvement in cisplatin-induced anorexia via hypothalamic
ghrelin
In vivo Yakabi et al. (2010)
Rikkunshito Cancer-cachexia Improvement in anorexia–cachexia, prolongation of survival
and reduction in anxiety-related behaviors
In vitro
and in
vivo
Fujitsuka et al. (2011)
Rikkunshito Stomach cancer Improvement in anorexia and body composition In vivo Terawaki et al. (2013)
Rikkunshito Esophageal cancer Improvement in anorexia, mood, QOL, and ADL Clinical Seike et al. (2011)
Rikkunshito Cisplatin-induced anorexia Improvement in anorexia Clinical Ohno et al. (2011)
Rikkunshito After gastrectomy Improvement in gastrointestinal symptoms after gastrectomy Clinical Takiguchi et al. (2013)
G-CSF, granulocyte-colony stimulating factor; TNF-α, tumor necrosis factor alpha; IFN-γ, interferon-gamma; CD4, cluster of differentiation 4; IL-4, interleukin-4; NK,
natural killer; Th2, T helper 2; GM-CSF, granulocyte macrophage colony-stimulating factor; IL-12, interleukin-12; IL-18, interleukin-18; CEA, carcinoembryonic antigen;
CA19-9, carbohydrate antigen 19-9; PC-SPES, prostate cancer-SPES; PSA, prostate specific antigen; QOL, quality of life; ADL, activities of daily living.
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development of anorexia–cachexia syndrome. Proinﬂammatory
cytokines—including IL-6, IL-1 beta, TNF-alpha and IFN-
gamma—are possible mechanisms that may cause reduced
caloric intake along with increased catabolic wasting, while anti-
inﬂammatory cytokines, such as IL-10, IL-12, IL-4, and IL-15
have been found to have anti-cachectic properties (Amitani et al.,
2013).
Proinﬂammatory cytokines can cause wasting,
malnourishment, and eventually death by increasing the
levels of the corticotropin-releasing factor (CRF; Ramos et al.,
2004). Proinﬂammatory cytokines also provoke eﬀects to mimic
leptin signaling, which result in suppressed orexigenic ghrelin
and neuropeptide Y. Therefore, anorexia and cachexia is induced,
which is not counteracted by the usual compensatory response
(Suzuki et al., 2013).
IL-6 plays an important role in anorexia–cachexia syndrome
(Barton, 2005). IL-6 also regulates fat metabolism in muscle,
which causes a rise in fatty acid oxidation and attenuates
the lipogenic eﬀects of insulin. Another proinﬂammatory
cytokine, TNF-alpha, is reported to be increased in patients
with cancer cachexia (Argiles et al., 2003). TNF-alpha
binds to its receptor and induces activation of the nuclear
factor (NF)-kappaB family of transcription factors (Von
Haehling et al., 2002). Leukemia inhibitory factor induces
anorexia by directly activating proopiomelanocortin neurons
(Grossberg et al., 2010). Adrenocorticotropic hormone
(ACTH) expresses leukemia inhibitory factor in the pituitary
and prompts pro opiomelanocortin and ACTH release
in response to inﬂammation (Chesnokova and Melmed,
2000).
Proinﬂammatory cytokines also induce cancer-related muscle
wasting. It has been reported that acute and chronic central
administration of IL-1 beta causes muscle atrophy (Braun
et al., 2011). Thus, proinﬂammatory cytokines can induce
central nervous system (CNS) inﬂammation, leading to muscle
atrophy through stimulation of the hypothalamic–pituitary–
adrenal (HPA) axis (Braun et al., 2011).
On the other hand, the anti-cachectic eﬀect by anti-
inﬂammatory cytokines has attracted a certain amount of
attention. Researchers have shown that anti-inﬂammatory
cytokines inhibit syndrome progression and prolong survival
time by using the Myc/mTOR-driven animal model of anorexia–
cachexia syndrome. This model has deregulated expression of
cytokines, including IL-10 (Robert et al., 2012). The other
anti-inﬂammatory cytokine, IL-15, increases glucose uptake in
skeletal muscle and can be an anabolic factor for skeletal muscle
(Busquets et al., 2006). IL-12 has been found to moderate body
weight loss and other abnormalities associated with cachexia
in mice with colon-26 carcinoma. Collectively, these ﬁndings
begin to help shed light on the possibility of new therapeutic
treatments for anorexia–cachexia syndrome (Amitani et al.,
2013).
The number of reports on the interaction of herbal medicines
with anticancer agents is also on the increase. Many Kampo
products and active components have been reported to moderate
an array of processes in cancer cell growth, invasion and
metastasis by modulating a broad range of molecular targets,
including: cyclooxygenase-2 (COX-2), NF-kappaB and NF
erythroid 2-related factor 2-mediated antioxidant signaling
pathways (Wang et al., 2010). The active components that have
demonstrated chemopreventive eﬀects may serve as potential
principal agents for the design of new and less toxic agents for
cancer chemoprevention (Wang et al., 2010).
Ginseng and Astragalus, which are contained in hozai, are
reported its immunomodulatory function in preclinical and
clinical studies (Keith and Mark, 2003). Ginseng stimulates NK
cell and macrophage activities (Kim et al., 1990; Akagawa et al.,
1996). Ginseng and Astragalus also inﬂuences cytokine secretion.
Ginseng stimulates IL-2 and Astragalus produces IL-6 and TNF-
alfa (Keith and Mark, 2003).
While each natural remedy has been revealed its eﬀect,
Kampo formula consists of multicomponent herbs. Since each
herb has close interaction, Kampo formula shows its eﬀect
as total mechanism. The development of multicomponent
herbal medicines, Kampo, may be valuable toward the potential
management of complex diseases and new drug discoveries
(Suzuki et al., 2012).
The Translational Aspect of Each Hozai
Formula
Hochu-ekki-to
Hochu-ekki-to consists of: the herbs Astragali radix, Atractylodis
lanceae rhizoma, Ginseng radix, Angelicae radix, Bupleuri radix,
Zizyphi fructus, Aurantii nobilis pericarpium, Glycyrrhizae radix,
Cimicifugae rhizome, and Zingiberis rhizome.
Hochu-ekki-to has been found to reduce in vivo tumor activity
in rodent cancer models and treated syngeneic animals have
also demonstrated repression in tumor growth. The splenic
natural killer cells of rats treated with Hochu-ekki-to revealed a
heightened cytotoxicity against tumors, along with the discovery
of a potent inhibitory mechanism on tumor growth via the
enhancement of natural killer cell activity (Cho et al., 1991).
Another study showed that Hochu-ekki-to inhibited the spread
of hepatoma cell lines by stimulating apoptosis and halting
G0/G1 (Kao et al., 2001). In addition to the inhibitory eﬀect
of Hochu-ekki-to on tumor growth, immunological outcomes
have been reported. One study regarding the immunological
eﬀects of Hochu-ekki-to showed that it stimulated peripheral
blood mononuclear cells (PBMNCs) to produce granulocyte-
colony stimulating factor (G-CSF) and TNF-alpha (Kao et al.,
2000). Also, the temporal dose stimulation of murine normal
colonic epithelial cell lines caused a signiﬁcant increase in
the levels of granulocyte colony-stimulating (Matsumoto et al.,
2010a).
Hochu-ekki-to has also demonstrated inhibitory eﬀects on
endometrial carcinogenesis due to a decrease in the expression of
c-jun, TNF-alpha, and estrogen receptors alpha and beta (Onogi
et al., 2006). The oral administration of this herbal compound
has also been shown to increase IFN-gamma secretion from
lymphocytes, which increases L-selectin positive B lymphocytes,
which is associated with boosting IgA immune response
against intestinal antigens (Matsumoto et al., 2010b). These
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studies suggest that Hochu-ekki-to possesses chemotherapeutic
eﬀects.
Dose-dependent use of Hochu-ekki-to suppresses DNA
synthesis and induces apoptosis that inhibit the spread of
human breast cancer cell lines. Additionally, Hochu-ekki-to
stimulated the phosphorylation of c-Jun NH2-terminal kinase
(JNK), and pretreatment of breast cancer cells with the JNK
inhibitor SP600125 eradicated apoptosis (Volate et al., 2009).
Furthermore, combined treatment of Hochu-ekki-to and 5-
FU improved the apoptotic eﬀectiveness of 5-FU in breast
cancer cell lines (Volate et al., 2009). These data suggested
that Hochu-ekki-to has chemotherapeutic eﬀects (Volate et al.,
2009).
Hochu-ekki-to was shown to ameliorate cachexia induced
by colon-26 adenocarcinoma cells in mice. Although the
controlled treatment study did not demonstrate reduced tumor
growth, it showed signiﬁcant mitigation in the reduction of
carcass weight, food and water intake. Also, the weight of
the gastrocnemius and fat tissue around the testes and a
decrease in serum triglyceride level was noted (Yae et al.,
2012). The mechanisms by which Hochu-ekki-to mediated
these eﬀects were proposed to involve a reduction in the
serum IL-6 and expression level in macrophages (Yae et al.,
2012).
Hochu-ekki-to has also been shown to have a preventive
eﬀect against chemically induced carcinoma of the biliary tract
(Tsuneoka et al., 2009) and to reduce cancer-related fatigue
(Jeong et al., 2010).
While ﬁndings thus far are encouraging, more rigorous trials
are needed to conﬁrm the eﬃcacy of Hochu-ekki-to for use in
cancer patients.
Juzen-taiho-to
Juzen-taiho-to consists of the herbs: Astragali radix, Rehmanniae
radix, Paeoniae radix, Angelicae radix, Poria radix, Glycyrrhizin
radix, Ginseng radix, Cinnamomi cortex, Cnidii rhizoma, and
Atractylodis lanceae rhizoma.
Juzen-taiho-to was found to augment signiﬁcantly the
production of granulocyte-macrophage colony-stimulating
factor (GM-CSF) but did not augment that of G-CSF by cultured
human PBMNCs (Kubota et al., 1992). It was also used to treat
animals with liver tumors, where it showed a signiﬁcantly higher
survival rate without any side eﬀects compared to the untreated
controls (Tatsuta et al., 1994; Ohnishi et al., 1998). It has been
suggested that oral administration of Juzen-taiho-to inhibits liver
metastasis of cancer through a mechanism that is mediated by
activation of the host immune system, including activation of:
macrophages, T-cells, B-cells, and natural killer cells (Ohnishi
et al., 1998).
The cytokine IL-18 was the most notable up-regulated of the
high number of cytokines that were assayed in the serum of
patients with liver function disorders under long-term Juzen-
taiho-to administration (Fujiki et al., 2008). It was also found
that the oral administration of Juzen-taiho-to might stimulate
the expression of IL-12 in the early stage, and IL-18 in the
chronic phase, followed by natural killer-T cell stimulation. The
mechanism of activation following immunological restoration
could contribute to the anti-tumor eﬀects (Fujiki et al.,
2008).
The oral administration of Juzen-taiho-to in mice with B16
melanoma was found to inhibit tumor metastasis in the lungs.
The suggested mechanism was the increase in the production of
IL-12, which is responsible for the activation of both natural killer
cells and natural killer-T cells in the lungs, resulting in inhibition
of B16 melanoma cell metastasis in the lungs (Matsuda et al.,
2011).
Despite the emerging literature, it is still not clear which
of the compounds in Juzen-taiho-to handle the stimulation
of individual cell types. Recently, Takaoka et al. (2014)
reported a “biomarker-guided screening” method that identiﬁed
intercellular adhesion molecule-1 by using a DNA array for
macrophages via the puriﬁcation of compounds responsible
for stimulating macrophage activity of Juzen-taiho-to. The
screening method resulted in the distillation of a glycolipid
mixture containing beta-glucosylceramides, which stimulated
intercellular adhesion molecule-1 expression in primary
dendritic cells and primary CD14+ macrophages.
A preventive eﬀect was demonstrated by using Juzen-taiho-to
on endometrial carcinogenesis via the suppression of estrogen-
induced c-fos/jun-expression that created an inhibitory eﬀect
on E2-related endometrial carcinogenesis in mice (Niwa et al.,
2001). It was also demonstrated that four herbs of Juzen-taiho-
to attenuated these eﬀects signiﬁcantly, and Shimotsu-to handled
the inhibition of estrogen-related endometrial carcinogenesis
(Lian et al., 2002).
Juzen-taiho-to was shown to reduce oxidative DNA damage,
inﬂammatory cell inﬁltration and cytokine expression, and these,
in turn, inhibited the development of liver tumors and the
recurrence of hepatocellular carcinoma after surgery (Tsuchiya
et al., 2008). Suppression of Kupﬀer cell function leading to a
decrease in pro-inﬂammatory cytokines and oxidants in the liver
was proposed to mediate the protective eﬀect of Juzen-taiho-to
against hepatocarcinogenesis.
Kampo formulas may be beneﬁcial for cancer patients
treated with chemotherapy or radiation therapy (Yamada, 1989).
The combination of Mitomycin C and Juzen-taiho-to showed
signiﬁcantly greater anti-cancer activity and longer survival times
than Mitomycin C alone (Komiyama et al., 1989; Yamada,
1989).
Juzen-taiho-to has been shown to reduce some of the
side eﬀects associated with anticancer drugs when combined
with UFT and TS-1 treatments that contain a ﬁve-ﬂuorouracil
derivative. Combined treatment with Juzen-taiho-to mitigated
weight loss (Sakamoto et al., 1991) and improved bone marrow
suppression (Ogawa et al., 2012) in UFT colon cancer treatment
in rats and TS-1 related cancer treatments, respectively.
Juzen-taiho-to creates radioprotective and anti-tumor
eﬀects by increasing the number and size of splenic CFU-S
(Ohnishi et al., 1990). This anti-tumor eﬀect has been markedly
demonstrated when combined with surgical excision or
with chemotherapeutic drugs. For example, a study that
used combined Juzen-taiho-to therapy with IFN-alpha on
experimental lung metastasis of murine renal cell carcinoma,
resulted in a dose-dependent inhibition of lung metastasis
Frontiers in Pharmacology | www.frontiersin.org 5 August 2015 | Volume 6 | Article 150
Amitani et al. CAM and Kampo in cancer
after ﬁve consecutive treatment doses in mice (Muraishi et al.,
2000).
Ninjin-yoei-to
Ninjin-yoei-to consists of the herbs Rehmanniae radix,
Astragali radix, Angelicae radix, Ginseng radix, Polygalae
radix, Glycyrrhizae radix, Paeoniae radix, Atractylodis rhizome,
Poria cortex, Cinnamomi cortex, Aurantii nobilis pericarpium,
and Schisandrae fructus.
There have been a few investigations that have demonstrated
the potential beneﬁts of Ninjin-yoei-to. Researchers discovered
that the compound increased natural killer cell activity after
2 days and lasted for a 1-week period in healthy people (Kamei
et al., 1998). A case study reported decreased tumor CEA and
CA19-9 markers in an older female with lung cancer after a 7-
weeks treatment. And her cough was eliminated along with an
improvement in appetite (Kamei et al., 2000). Cultured human
PBMNCs in the presence of Ninjin-yoei-to in vitro demonstrated
marked augmentation of GM-CSF production but not G-CSF
(Okamura et al., 1991).
Seisho-ekki-to
Seisho-ekki-to consists of the herbs: Atractylodis lanceae
rhizoma, Ginseng radix, Ophiopogonis tuber, Astragali radix,
Aurantii nobilis pericarpium, Angelicae radix, Phellodendri cortex,
Glycyrrhizae radix, and Schisandrae fructus.
Seisho-ekki-to has been shown to have above average
anti-oxidation activity. The eﬀects of the combination of
Seisho-ekki-to and Scutellaria baicalensis were evaluated in
cancer-induced cachectic mice upon receiving chemotherapy
with 5-FU. The combined application resulted in a signiﬁcant
decrease in tumor masses and losses of carcass and/or
gastrocnemius muscles (Wang et al., 2012) and increases in
both the Th1/Th2 ratio, NK cytotoxicity, and decreases in the
expression of NF-kappaB and muscle RING ﬁnger protein-1
(MuRF-1) in the gastrocnemius muscle.
Rikkunshi-to
Rikkunshi-to has been used to treat various gastrointestinal tract
disorders and includes the herbs: Atractylodis lanceae rhizoma,
Ginseng radix, Pinelliae tuber, Poria cocos, Zizyphi fructus,
Aurantii nobilis pericardium, Radix Glycyrrhizae, Zingiberis
rhizome, and Atractylidis lanceae rhizoma.
Tominaga et al. (2011) clariﬁed the mechanism of Rikkunshi-
to activity that underlies its clinical eﬀect. It has been shown that
it enhances gastric motility by causing an antagonistic eﬀect on
the 5-HT3 receptor. The hypothesis is that this may occur due
to a singular transmission path that diﬀers from that facilitated
by the 5-HT3 receptor-antagonist (Tominaga et al., 2011). In
a clinical study, Rikkunshi-to was demonstrated to signiﬁcantly
attenuate gastrointestinal symptoms after gastrectomy (Takiguchi
et al., 2013). In use with animals and patients with cancer, it
showed a reduction in anorexia, GI dysmotility, muscle wasting,
anxiety and extended survival time (Fujitsuka et al., 2011). In a
double-blind controlled trial in rats with cancer, it signiﬁcantly
ameliorated dysmotility-like dyspepsia and improved upper
gastrointestinal symptoms (Hattori, 2010).
The combination of Rikkunshi-to with an anti-emetic drug
has demonstrated some eﬀectiveness against anorexia and
vomiting induced by chemotherapy. It was recently indicated
that it ameliorates cisplatin-induced anorexia by facilitating an
increase in circulating ghrelin concentration (Yakabi et al., 2010).
A recent RCT was conducted on advanced esophageal cancer
patients who received combined chemotherapy with docetaxel/5-
FU/CDDP and Rikkunshi-to. The combined treatment was
eﬀective in reducing the symptomatic occurrence of vomiting,
nausea and anorexia. It also improved the quality of life, mood
and activities of daily living (Seike et al., 2011). Another clinical
study also showed that Rikkunshi-to reduced cisplatin-induced
anorexia (Ohno et al., 2011).
In rats with tumors, a CRF receptor antagonist was
shown to mitigate cancer anorexia–cachexia syndrome, and
administration of the 5-HT2cR antagonist or Rikkunshi-to
reduced hypothalamic CRF levels along with behaviors that
are generally associated with anxiety that may lead to better
quality of life (Fujitsuka et al., 2011). Another study found
that the antrum and duodenum contraction rates in rats
were improved after Rikkunshi-to treatment, owing to selective
serotonin re-uptake inhibitor improvement via the enhancement
of the circulating ghrelin and signaling (Terawaki et al.,
2013).
These ﬁndings show that Rikkunshi-to may be useful
for treating anorexia and may provide a new strategy for
improvement of upper gastrointestinal dysfunction (Terawaki
et al., 2014). Several studies have demonstrated that ghrelin
or ghrelin receptor agonists were eﬀective in the treatment of
cancer cachexia (Fujitsuka et al., 2012). Rikkunshi-to has been
shown to stimulate endogenous ghrelin secretion by blocking the
5-HT 2b/2c receptor pathway and enhancing ghrelin receptor
activity (Fujitsuka et al., 2012). A study in rodents with tumors
clariﬁed that the active component hesperidin improved the
eﬀectiveness of ghrelin secretion while atractylodin improved
receptor signaling and extended survival (Fujitsuka et al.,
2011). Thus, Rikkunshi-to may provide a potential treatment
method for anorexia, muscle wasting, and may prolong survival
(Fujitsuka et al., 2012).
Other Western Herbs Used as Cancer
Treatments
In Western countries, herbs such as Iscador, Essiac, Pau
D’Arco tea and cannabinoids are used commonly (Cheng et al.,
2012). Also important is the herbal treatment Prostate Cancer-
SPES (PC-SPES) that has taken attention for PC treatment.
PC-SPES consists of eight natural substances; Reishi, Baikal
skullcap, Rabdosia, Dyer’s woad, Saw palmetto, San-Qi Ginseng,
Dendranthema morifolium, and Chinese licorice (Marks et al.,
2002). For the past 20 years, men have used PC-SPES for
prostate health. The combined name of this herb was developed
from abbreviating the term PC and from the Latin word for
hope, spes. PC-SPES ﬁrst gained attention in a New England
Journal of Medicine article that discussed its estrogenic eﬀects
on men and warned against unregulated use (Dipaola et al.,
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1998). In clinical case reports, PC-SPES decreased PSA levels,
which increased after discontinuation of PC-SPES (Moyad et al.,
1999; de la Taille et al., 2000; Oh et al., 2002; Olaku and White,
2011).
St. John’s wort is also an herb that has been commonly used
by the public. A clinical study showed that the administration
of St. John’s wort acted to decrease the plasma levels of SN-38
(the active metabolite of irinotecan) by 42% in cancer patients.
In individuals without cancer, St. John’s wort has been shown to
decrease the plasma levels of imatinib by 32% after 2 weeks of
administration. Induction or inhibition of Cytochrome P450 or
transporters was considered to be an essential mechanism (He
et al., 2010).
Anticancer drugs that experience phase one/two metabolisms
are found to be substrates of P-glycoprotein, breast cancer
resistance protein and multidrug resistance-associated proteins.
In combination with anticancer drugs, the mechanistic properties
of these proteins are considered the key to herbal-anticancer drug
interactions. However, more studies need to be done investigating
harmful interactions (Yang et al., 2010).
Yet, when considering the herbal therapy used in the
treatment of cancer patients, preclinical ﬁndings of clinical
research must be considered. Both of risks and beneﬁts of herbal
therapy need to be discussed openly with patients (Eng, 2010).
Thus, it is helpful to understand the eﬀects and bioavailability
of phytopharmaceuticals for developing new therapy approaches
(Huang et al., 2008).
Functional Foods
Maitake mushrooms (Grifola frondosa), have also demonstrated
anticancer activity by increasing immune-competent cell activity
that occurs from the combination of beta-1,6 glucan and beta-
1,3 branched chains (Adachi et al., 1988; Hishida et al., 1988).
An antitumor eﬀect was found when the extract (MD-fraction)
from maitake mushrooms was applied to rodents with tumors.
The mechanism proposed was the activation of macrophages, T
and natural killer cells that in turn enhanced the immune system
(Inoue et al., 2002), and the eﬀects have been found in other
animal studies as well (Kodama et al., 2002). The use of whole
maitake powder combined with MD-fraction was tested in a non-
random case series on stage III-V cancer patients. More than half
of liver cancer patients (∼58%), breast cancer patients (∼70%),
and lung cancer patients (∼63%) experienced regression and
improvements symptomology. Other combination approaches
have also shown to be eﬀective, chemotherapy plus maitake
improved immune-competent cell activities ∼30% more than
chemo alone (Kodama et al., 2002). The proposed mechanism of
MD fraction to limit cancer progression comes primarily via the
stimulation of natural killer cell activity (Kodama et al., 2003).
Green tea is the most widely consumed beverage after
water. The major bioactive constituents are catechins, of which
epigallocatechin-3-gallate, epicatechin, epicatechin-3-gallate, and
epigallocatechin are the major components. The anticancer
activities of green tea were highlighted recently (Zhang et al.,
2014; Butt et al., 2015).
The catechin, epigallocatechin-3-gallate, has strong anti-
oxidant and anti-inﬂammatory activity, and it aﬀects several
signal transduction pathways relevant to cancer development
(Lambert et al., 2010). The anticancer eﬀect of catechins is
enhanced when they are combined with anticancer drugs
(Suganuma et al., 2011; Yu et al., 2014). A large number of
cohort studies and controlled randomized trials have suggested
that green tea reduces the risk of cancer (Gao et al., 1994;
Sasazuki et al., 2004). However, the opposite results—that there
is no association between green tea consumption and the risk of
cancer—have also been reported (Tsubono et al., 2001; Koizumi
et al., 2003; Suzuki et al., 2004). The mechanisms by which
green tea controls cancer insurgency have been found to occur
in cell culture and animal studies. It is proposed that these
mechanisms induce apoptosis, control cell growth arrest, alter
the expression of cell-cycle regulatory proteins, activate killer
caspases and suppress NF kappa-B activation (Butt et al., 2015).
Based on the above reports, careful interpretation is needed
when considering the preventive eﬀects of green tea on cancer.
Future intervention trials regarding functional foods including
MD-fraction and green tea are warranted.
The Mechanism and Management of
Emotional Stress for Cancer
Mind-body therapies are growing in popularity due to the
need of cancer patients to manage emotional stress (Elkins
et al., 2010). Studies have evaluated therapies such as relaxation,
biofeedback, meditation, hypnosis, yoga, art, music, and mind-
body exercises such as Tai Chi and Qigong. These therapies have
demonstrated various eﬀects on improved mood, reduced pain,
anxiety, insomnia and hot ﬂashes, along with anticipatory and
treatment-related nausea.
Psychological Interventions and Immunity
A large number of studies have suggested a relationship between
stress, coping factors and cancer (Monjan and Collector, 1977;
Sklar and Anisman, 1979; Laudenslager et al., 1983; Chilvers
and Peto, 1986; Chrousos, 1995). A recent study showed that
chronic stress might cause social aversion via the glucocorticoid
receptor in dopaminoceptive neurons (Barik et al., 2013). There
are two major pathways activated by stressors: the HPA axis and
the sympathetic-adrenal-medullary (SAM) axis (Chrousos, 1995;
Glaser and Kiecolt-Glaser, 2005). CRF and ACTH found in high
concentrations during stress, have a critical role in decreasing
the production of many cytokines and inﬂammation mediators.
Both mental stress and depression are considered to be associated
with NK cell activities and decreased T-cell that aﬀect processes
of immune surveillance of tumors (Reiche et al., 2004).
The links between psychological states and cancer progression
have been studied. The response of the HPA axis to stressors
impairs the immune response by provoking the release of
pituitary and adrenal hormones such as ACTH, cortisol,
catecholamines, growth hormone and prolactin. The levels of
these hormones are inﬂuenced by negative events or emotions
(Glaser and Kiecolt-Glaser, 2005). The HPA axis and the SAM
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axis act directly or indirectly on cell surface receptors by inducing
dysregulation of the production of cytokines such as IL-6, IFN-
γ, IL-1, and TNF-alpha. Many studies suggest that psychological
stress aﬀects various aspects of the immune response at
cellular, molecular and genetic levels via the CNS, hormones,
cytokines, several neurotransmitters and neuropeptides. The
neuroendocrine and immune system share several mediators and
receptors, and they regulate the immune system. CRF has a major
role in regulating psychoneuroimmunology. CRF aﬀects the HPA
axis and stimulates elevation in stress hormone levels, which in
turn leads to deregulated immune function (Glaser and Kiecolt-
Glaser, 2005). In turn, CRF activities in HPA are stimulated by
proinﬂammatory cytokines (Shintani et al., 1993; Chen et al.,
2010).
Serotonin also plays a key role in the progress of cancer
anorexia (Rossi-Fanelli and Laviano, 2003). Increased levels of
the serotonin precursor, plasma and brain tryptophan may be
related to the increased serotonergic activity seen in the cancer
anorexia–cachexia syndrome. A recent study revealed the role
of hypothalamic 5-HT-CRF receptor pathway, which regulates
ghrelin secretion in cancer anorexia–cachexia (Fujitsuka et al.,
2011; Suzuki et al., 2013). Both 5-HT(1a) and 5-HT(2c) receptors
inﬂuence anxiety-like behavior (Holmes et al., 2003; Heisler et al.,
2007). Currently, the eﬀect of elevated ghrelin is unclear. Some
studies report that it may induce anxiety while others state that it
may produce an anxiolytic-like response in animals that enables
coping with stress (Chuang and Zigman, 2010).
Cytokine-Mediated Depression and Anxiety
Proinﬂammatory cytokines may be related to the risk of
depressive symptoms, shown in patients with cancer (Numakawa
et al., 2014). The responses of cortisol to stress show crucial
psychosomatic eﬀects on the central nervous and immune
systems as well as other tissues in the body. A cortisol treatment
study also demonstrated a signiﬁcant reduction in the production
of IL-6 and generated an association with the impairment of
memory recovery caused by emotional distress (Rohleder et al.,
2009).
It has also been reported that central administration of IL-
1 beta caused sickness and depressive-like behaviors with the
increase of IL-6 in an animal model, whereas the administration
of IL-6 resulted in depressive-like behavior (Sukoﬀ Rizzo
et al., 2012). These studies suggest that diﬀerent cytokines are
involved in both depression and sickness behaviors. Particularly
elevated IL-6 may play a key role in the development of
depression.
It has also been reported that a negative emotiogenic exposure
can be related to speciﬁc immune reactions (Kalinichenko et al.,
2014a). Furthermore, reduction of pro-inﬂammatory cytokine
levels in active rats exposed to stress was less pronounced after
intraperitoneal preinjection of melatonin. In passive animals,
exogenous melatonin inverted the post-stress changes in the
serum levels of the pro-inﬂammatory IL-2 cytokine and anti-
inﬂammatory IL-4 and IL-10 cytokines (Kalinichenko et al.,
2014b).
It was shown in a clinical study that emotional symptoms
are related to the levels of several cytokines, such as IL-6, in
several diseases, including rheumatoid arthritis and hemodialysis
patients (Montinaro et al., 2010). Colorectal cancer patients had
increased serum levels of IL-6, IL-1beta, TNF-alpha, and IL-8 but
lower IL-10 concentrations. A correlation analysis of the Hospital
Anxiety and Depression Scale score and cytokine levels revealed
positive associations with the domain of anxiety/depression with
IL-6, IL-1beta and TNF-alpha and a negative correlation with
IL-10. These results suggested that circulating proinﬂammatory
cytokines might be involved in the pathophysiology of anxiety
and depression in cancer patients (Oliveira Miranda et al.,
2014).
Mind and Body Medicine
Yoga
Yoga is a mind-body exercise that combines mind, body and
breath, and users tend to be female with higher levels of education
(Park et al., 2013). One study found that despite the interest
in a yoga therapy program for cancer survivors, there were
implementation barriers (Slocum-Gori et al., 2013).
Yoga therapy has demonstrated beneﬁcial eﬀects on
improvement of components of health-related quality of
life and symptom indices in survivors of breast cancer, survivors
of non-small cell lung cancer and in patients undergoing
radiotherapy (Mustian et al., 2013; Chandwani et al., 2014;
Fouladbakhsh et al., 2014; Martin and Keats, 2014). Components
of health-related quality of life were evaluated using the FACT-B
survey and the breast cancer-speciﬁc well-being and Trial
Outcome Index. Signiﬁcant improvement was found in physical,
social, emotional, and functional well-being but not social
well-being (Levine and Balk, 2012). In a 12-weeks restorative
yoga intervention, inﬂammation-related gene expression was
reduced in breast cancer survivors (Bower et al., 2014). Other
studies suggested the eﬀectiveness of yoga for women with
secondary arm lymphoedema from breast cancer treatment
(Loudon et al., 2012, 2014). While there may be some apparent
beneﬁts in cancer patients that use yoga therapy, more research
remains to be done, and the mechanisms by which yoga induces
these eﬀects need to be understood.
Mindfulness-Based Stress Reduction
“Mindfulness” can be described as an engagement in a
special form of meditation and a state of consciousness,
depicted as a broadminded moment-to-moment awareness
and a curious experiential openness and acceptance toward
one’s own experiences (Bishop et al., 2004). The origin of
mindfulness techniques, as used in psychosocial care, is derived
from Siddhartha Gautama, the historical Buddha. Today the
most commonly used mindfulness-based interventions are the
mindfulness-based stress reduction (MBSR) and mindfulness-
based cognitive therapy (Baer, 2003). The evidence that MBSR
supports patients with cancer has been explored. Many outcomes
support the eﬀect of MBSR in improvement of mood, stress,
anxiety, fear of recurrence, adjustment, HRQoL, and locus of
control (Lengacher et al., 2012, 2014). The mechanism that
has been suggested to underlie these eﬀects is that MBSR
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reduces cortisol levels and the levels of cytokines such as IL-
6 (Carlson et al., 2007; Witek-Janusek et al., 2008; Lengacher
et al., 2012). A study demonstrated thatMBSR participants versus
non-participants had re-established levels of immunoregulatory
factors, such as PBMNC natural killer cell activity and cytokine
regulation, and the study additionally demonstrated a reduction
in cortisol levels, improved HRQoL, and increased coping
eﬀectiveness (Witek-Janusek et al., 2008).
Conclusion
Increased evidence has shown that CAM, especially Kampo and
mind-body therapies, may serve as beneﬁcial adjuncts to cancer
treatment. Health professionals need to be aware of such evidence
and to use these interventions as complementary treatments in an
integrated way. Health professionals are also required to support
patient evidence-based decision-making since patients want to
try everything they can alleviate the burden of cancer. In this vein,
further studies, particularly double-blind studies, are needed to
verify the eﬃcacy of CAM and to obtain high-quality evidence to
support the use of CAM.
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